Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Dec;64(12):4922–4927. doi: 10.1128/iai.64.12.4922-4927.1996

Antiendotoxin activity of cationic peptide antimicrobial agents.

M Gough 1, R E Hancock 1, N M Kelly 1
PMCID: PMC174469  PMID: 8945527

Abstract

The endotoxin from gram-negative bacteria consists of a molecule lipopolysaccharide (LPS) which can be shed by bacteria during antimicrobial therapy. A resulting syndrome, endotoxic shock, is a leading cause of death in the developed world. Thus, there is great interest in the development of antimicrobial agents which can reverse rather than promote sepsis, especially given the recent disappointing clinical performance of antiendotoxin therapies. We describe here two small cationic peptides, MBI-27 and MBI-28, which have both antiendotoxic and antibacterial activities in vitro and in vivo in animal models. We had previously demonstrated that these peptides bind to LPS with an affinity equivalent to that of polymyxin B. Consistent with this, the peptides blocked the ability of LPS and intact cells to induce the endotoxic shock mediator, tumor necrosis factor (TNF), upon incubation with the RAW 264.7 murine macrophage cell line. MBI-28 was equivalent to polymyxin B in its ability to block LPS induction of TNF by this cell line, even when added 60 min after the TNF stimulus. Furthermore, MBI-28 offered significant protection in a galactosamine-sensitized mouse model of lethal endotoxic shock. This protection correlated with the ability of MBI-28 to reduce LPS-induced circulating TNF by nearly 90% in this mouse model. Both MBI-27 and MBI-28 demonstrated antibacterial activity against gram-negative bacteria in vitro and in vivo against Pseudomonas aeruginosa infections in neutropenic mice.

Full Text

The Full Text of this article is available as a PDF (196.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham E., Wunderink R., Silverman H., Perl T. M., Nasraway S., Levy H., Bone R., Wenzel R. P., Balk R., Allred R. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995 Mar 22;273(12):934–941. [PubMed] [Google Scholar]
  2. Baumgartner J. D., Heumann D., Gerain J., Weinbreck P., Grau G. E., Glauser M. P. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies. J Exp Med. 1990 Mar 1;171(3):889–896. doi: 10.1084/jem.171.3.889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beutler B. A., Milsark I. W., Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol. 1985 Dec;135(6):3972–3977. [PubMed] [Google Scholar]
  4. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  5. Bortolussi R., Ferrieri P., Björkstén B., Quie P. G. Capsular K1 polysaccharide of Escherichia coli: relationship to virulence in newborn rats and resistance to phagocytosis. Infect Immun. 1979 Jul;25(1):293–298. doi: 10.1128/iai.25.1.293-298.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brandtzaeg P., Kierulf P., Gaustad P., Skulberg A., Bruun J. N., Halvorsen S., Sørensen E. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis. 1989 Feb;159(2):195–204. doi: 10.1093/infdis/159.2.195. [DOI] [PubMed] [Google Scholar]
  7. Christ W. J., Asano O., Robidoux A. L., Perez M., Wang Y., Dubuc G. R., Gavin W. E., Hawkins L. D., McGuinness P. D., Mullarkey M. A. E5531, a pure endotoxin antagonist of high potency. Science. 1995 Apr 7;268(5207):80–83. doi: 10.1126/science.7701344. [DOI] [PubMed] [Google Scholar]
  8. Cohen J., McConnell J. S. Antibiotic-induced endotoxin release. Lancet. 1985 Nov 9;2(8463):1069–1070. doi: 10.1016/s0140-6736(85)90939-0. [DOI] [PubMed] [Google Scholar]
  9. Cryz S. J., Jr, Fürer E., Germanier R. Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice. Infect Immun. 1983 Mar;39(3):1067–1071. doi: 10.1128/iai.39.3.1067-1071.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Darveau R. P., Hancock R. E. Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J Bacteriol. 1983 Aug;155(2):831–838. doi: 10.1128/jb.155.2.831-838.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Freudenberg M. A., Keppler D., Galanos C. Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect Immun. 1986 Mar;51(3):891–895. doi: 10.1128/iai.51.3.891-895.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Galanos C., Freudenberg M. A., Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5939–5943. doi: 10.1073/pnas.76.11.5939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Greenman R. L., Schein R. M., Martin M. A., Wenzel R. P., MacIntyre N. R., Emmanuel G., Chmel H., Kohler R. B., McCarthy M., Plouffe J. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 1991 Aug 28;266(8):1097–1102. [PubMed] [Google Scholar]
  14. Hanasawa K., Tani T., Kodama M. New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber. Surg Gynecol Obstet. 1989 Apr;168(4):323–331. [PubMed] [Google Scholar]
  15. Hancock R. E., Falla T., Brown M. Cationic bactericidal peptides. Adv Microb Physiol. 1995;37:135–175. doi: 10.1016/s0065-2911(08)60145-9. [DOI] [PubMed] [Google Scholar]
  16. Kelly N. M., Young L., Cross A. S. Differential induction of tumor necrosis factor by bacteria expressing rough and smooth lipopolysaccharide phenotypes. Infect Immun. 1991 Dec;59(12):4491–4496. doi: 10.1128/iai.59.12.4491-4496.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Levy O., Ooi C. E., Weiss J., Lehrer R. I., Elsbach P. Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli. J Clin Invest. 1994 Aug;94(2):672–682. doi: 10.1172/JCI117384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Little R. G., Kelner D. N., Lim E., Burke D. J., Conlon P. J. Functional domains of recombinant bactericidal/permeability increasing protein (rBPI23). J Biol Chem. 1994 Jan 21;269(3):1865–1872. [PubMed] [Google Scholar]
  19. Marra M. N., Wilde C. G., Collins M. S., Snable J. L., Thornton M. B., Scott R. W. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol. 1992 Jan 15;148(2):532–537. [PubMed] [Google Scholar]
  20. Marra M. N., Wilde C. G., Griffith J. E., Snable J. L., Scott R. W. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol. 1990 Jan 15;144(2):662–666. [PubMed] [Google Scholar]
  21. Mathison J. C., Wolfson E., Ulevitch R. J. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest. 1988 Jun;81(6):1925–1937. doi: 10.1172/JCI113540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mohler K. M., Torrance D. S., Smith C. A., Goodwin R. G., Stremler K. E., Fung V. P., Madani H., Widmer M. B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993 Aug 1;151(3):1548–1561. [PubMed] [Google Scholar]
  23. Moore R. A., Bates N. C., Hancock R. E. Interaction of polycationic antibiotics with Pseudomonas aeruginosa lipopolysaccharide and lipid A studied by using dansyl-polymyxin. Antimicrob Agents Chemother. 1986 Mar;29(3):496–500. doi: 10.1128/aac.29.3.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Piers K. L., Brown M. H., Hancock R. E. Improvement of outer membrane-permeabilizing and lipopolysaccharide-binding activities of an antimicrobial cationic peptide by C-terminal modification. Antimicrob Agents Chemother. 1994 Oct;38(10):2311–2316. doi: 10.1128/aac.38.10.2311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Piers K. L., Brown M. H., Hancock R. E. Recombinant DNA procedures for producing small antimicrobial cationic peptides in bacteria. Gene. 1993 Nov 30;134(1):7–13. doi: 10.1016/0378-1119(93)90168-3. [DOI] [PubMed] [Google Scholar]
  26. Piers K. L., Hancock R. E. The interaction of a recombinant cecropin/melittin hybrid peptide with the outer membrane of Pseudomonas aeruginosa. Mol Microbiol. 1994 Jun;12(6):951–958. doi: 10.1111/j.1365-2958.1994.tb01083.x. [DOI] [PubMed] [Google Scholar]
  27. Prins J. M., Kuijper E. J., Mevissen M. L., Speelman P., van Deventer S. J. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun. 1995 Jun;63(6):2236–2242. doi: 10.1128/iai.63.6.2236-2242.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rogy M. A., Moldawer L. L., Oldenburg H. S., Thompson W. A., Montegut W. J., Stackpole S. A., Kumar A., Palladino M. A., Marra M. N., Lowry S. F. Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI. Ann Surg. 1994 Jul;220(1):77–85. doi: 10.1097/00000658-199407000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rogy M. A., Oldenburg H. S., Calvano S. E., Montegut W. J., Stackpole S. A., Van Zee K. J., Marra M. N., Scott R. W., Seilhammer J. J., Moldawer L. L. The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock. J Clin Immunol. 1994 Mar;14(2):120–133. doi: 10.1007/BF01541345. [DOI] [PubMed] [Google Scholar]
  30. Shenep J. L., Barton R. P., Mogan K. A. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis. J Infect Dis. 1985 Jun;151(6):1012–1018. doi: 10.1093/infdis/151.6.1012. [DOI] [PubMed] [Google Scholar]
  31. Stokes D. C., Shenep J. L., Fishman M., Hildner W. K., Bysani G. K., Rufus K. Polymyxin B prevents lipopolysaccharide-induced release of tumor necrosis factor-alpha from alveolar macrophages. J Infect Dis. 1989 Jul;160(1):52–57. doi: 10.1093/infdis/160.1.52. [DOI] [PubMed] [Google Scholar]
  32. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  33. Van Zee K. J., Kohno T., Fischer E., Rock C. S., Moldawer L. L., Lowry S. F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4845–4849. doi: 10.1073/pnas.89.11.4845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Warren H. S., Amato S. F., Fitting C., Black K. M., Loiselle P. M., Pasternack M. S., Cavaillon J. M. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med. 1993 Jan 1;177(1):89–97. doi: 10.1084/jem.177.1.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Ziegler E. J., Fisher C. J., Jr, Sprung C. L., Straube R. C., Sadoff J. C., Foulke G. E., Wortel C. H., Fink M. P., Dellinger R. P., Teng N. N. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991 Feb 14;324(7):429–436. doi: 10.1056/NEJM199102143240701. [DOI] [PubMed] [Google Scholar]
  36. van Deventer S. J., Buller H. R., ten Cate J. W., Sturk A., Pauw W. Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet. 1988 Mar 19;1(8586):605–609. doi: 10.1016/s0140-6736(88)91412-2. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES